Clinical trials: Oligodendroglioma of Brain
Recurrent Central Nervous System Neoplasm
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00619112
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT01165632
- Testing
- biopsy, computed tomography, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
This study will be aimed at investigating the effectiveness of a treatment for brain tumors called Photodynamic Therapy, or PDT.
- Trial name
- NCT01966809
- Testing
- Photofrin photodynamic therapy.
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Harry T Whelan, MD
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
This randomized phase II clinical trial studies the side effects and how well proton beam or intensity-modulated radiation therapy works in preserving brain function in patients with IDH mutant grade II or III glioma.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma
- Trial name
- NCT03180502
- Testing
- Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 34 sites in United States
- Volunteers
- 120 people
- Sponsor
- NRG Oncology
Malignant Glioma, Glioblastoma Multiforme
Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma
The purpose of this study is to evaluate the safety and biologically active dose of TM-601 in adult patients with recurrent malignant glioma.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma
- Trial name
- NCT00591058
- Testing
- TM-601
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- TransMolecular
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00268385
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide
- Where
- 17 sites in United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Ependymoma
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma
- Trial name
- NCT01082926
- Testing
- therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and determines the best dose of genetically modified neural stem cells and flucytosine when given together with leucovorin for treating patients with recurrent high-grade gliomas.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT02015819
- Testing
- E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors
CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas
RATIONALE: Drugs used in chemotherapy, such as CC-8490, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00074243
- Testing
- CC-8490
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
This partially randomized phase I/II trial studies the side effects and the best dose of anti-endoglin monoclonal antibody TRC105 when given together with bevacizumab and to see how well they work in treating patients with…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT01648348
- Testing
- Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis
- Where
- 308 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002753
- Testing
- iodine I 131 monoclonal antibody 81C6
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00516607
- Testing
- enzastaurin hydrochloride, temozolomide, pharmacological study
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma
RATIONALE: New imaging procedures such as magnetic resonance imaging may improve the ability to detect the extent of newly diagnosed cancer.
- Trial name
- NCT00005082
- Testing
- biopsy, magnetic resonance imaging
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00045110
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Medulloblastoma, Glioblastoma Multiforme
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer.
- Conditions
- Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS
- Trial name
- NCT04978727
- Testing
- SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
- Where
- 14 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Children's Oncology Group
Glioma, Glioblastoma Multiforme
Genetic Analysis of Brain Tumors
This study will analyze tissue and blood samples from patients with gliomas (a type of brain tumor) to develop a new classification system for these tumors.
- Conditions
- Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT00031538
- Where
- 3 sites in United States
- Volunteers
- 674 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment.
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma
- Trial name
- NCT02255461
- Testing
- palbociclib isethionate, pharmacological study, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pediatric Brain Tumor Consortium
Neoplasms, Brain, Glioblastoma Multiforme
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor.
- Conditions
- Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms
- Trial name
- NCT03911388
- Testing
- G207
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor
Cilengitide in Treating Children With Refractory Primary Brain Tumors
This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma
- Trial name
- NCT00063973
- Testing
- cilengitide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
- Trial name
- NCT00003461
- Testing
- surgical procedure, astatine At 211 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University